🏛️ Verified NIH Record • Updated 2026-07-21
CAN1012 in Pre-Malignant DCIS and LCIS (NCT07408856)
A Phase I/Ib Study Evaluating Intralesional TLR7 Agonist, CAN1012, in Pre-malignant Ductal Carcinoma in Situ and Lobular Carcinoma in Situ
🟡 Not Yet Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Providence Health & Services
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase I/Ib study evaluating CAN1012 in patients with ductal carcinoma in situ and lobular carcinoma in situ.
Who can join: Review the eligibility criteria below.
Location: Providence Portland Cancer Institute - Franz Clinic — Portland, Oregon
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Providence Portland Cancer Institute - Franz Clinic — Portland, Oregon
📞 Contact the Study Coordinator
Phone: (503) 215-1979
Email: canrsrchstudies@providence.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ductal Carcinoma in Situ
- Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions — Gainesville, Florida
- DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment — Berkeley, California
- Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ — Glendale, California
- Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ — Pittsburgh, Pennsylvania
- Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT) — Stuart, Florida
Explore by condition: All Ductal Carcinoma in Situ clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.